Chronic Diseases


Nightingale Health

Preventing heart disease and diabetes through a disruptive blood analysis platform

Team Lead

Antti Kangas

Basic Information

Our Solution

Nightingale Health

Our solution's stage of development:


Our solution:

Disruptive blood screening solution to cut heart disease and diabetes costs up to 25% by enabling preventive medicine in routine healthcare.

Our pitch:

We foresee our technology to have the potential to bring global costs of heart disease and diabetes down up to 25% and lower the mortality up to 15% within the next 10 years. This would translate to more than 300B USD annual global savings and enhance the lives of millions suffering of heart disease and diabetes.

Heart disease is the biggest cause of death globally. It is routinely diagnosed with a cholesterol test to treat and medicate people. Yet, 50% of people hospitalized for a heart attack have normal cholesterol values. It is widely acknowledged that the cholesterol test provides insufficient biological information to predict systemic diseases such as heart disease and diabetes. To capture the complexity of these systemic diseases, more comprehensive biological data is needed.

We introduce a disruptive blood screening solution where we take the same blood sample drawn for a cholesterol test and run it with our technology. Instead of the standard 4 biomarkers of a cholesterol test, the technology provides 228 blood biomarkers from a single blood sample, while keeping the cost the same. The comprehensive biomarker data has been shown to significantly improve heart disease and diabetes risk prediction in more than 100 peer-reviewed articles published in the leading biomedical journals.

The blood screening technology, developed during a decade of academic research, is based on nuclear magnetic resonance (NMR) spectroscopy and our proprietary biomarker quantification software. The technology is designed for rapid clinical uptake, by including the same cholesterol and glucose measures that the doctors currently use and know how to interpret.

With this solution, we aim to replace routine cholesterol testing in primary healthcare. The technology provides 224 additional biomarkers at no added cost while enabling the new era of disease risk prediction: 3-fold more accurately than current clinical tools, for early heart disease and diabetes detection.

The problem:


This information was not requested for Solve proposals at the time this solution was submitted.

Why our solution will solve the problem:


This information was not requested for Solve proposals at the time this solution was submitted.

Solution Team

  • Antti Kangas Co-Founder and Chief Technology Officer, Nightingale Health
to Top